These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 17200474)

  • 1. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
    ; Armstrong PW; Granger CB; Adams PX; Hamm C; Holmes D; O'Neill WW; Todaro TG; Vahanian A; Van de Werf F
    JAMA; 2007 Jan; 297(1):43-51. PubMed ID: 17200474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
    Granger CB; Mahaffey KW; Weaver WD; Theroux P; Hochman JS; Filloon TG; Rollins S; Todaro TG; Nicolau JC; Ruzyllo W; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1184-90. PubMed ID: 12925454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
    Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
    Verrier ED; Shernan SK; Taylor KM; Van de Werf F; Newman MF; Chen JC; Carrier M; Haverich A; Malloy KJ; Adams PX; Todaro TG; Mojcik CF; Rollins SA; Levy JH;
    JAMA; 2004 May; 291(19):2319-27. PubMed ID: 15150203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Trendelenburg M; Theroux P; Stebbins A; Granger C; Armstrong P; Pfisterer M
    Eur Heart J; 2010 May; 31(10):1181-7. PubMed ID: 20089518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Welsh RC; Granger CB; Westerhout CM; Blankenship JC; Holmes DR; O'Neill WW; Hamm CW; Van de Werf F; Armstrong PW;
    JACC Cardiovasc Interv; 2010 Mar; 3(3):343-51. PubMed ID: 20298996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes.
    Guptill JT; Mehta RH; Armstrong PW; Horton J; Laskowitz D; James S; Granger CB; Lopes RD
    Circ Cardiovasc Interv; 2013 Apr; 6(2):176-83. PubMed ID: 23549644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
    Mahaffey KW; Granger CB; Nicolau JC; Ruzyllo W; Weaver WD; Theroux P; Hochman JS; Filloon TG; Mojcik CF; Todaro TG; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1176-83. PubMed ID: 12925455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
    Armstrong PW; Fu Y; Westerhout CM; Hudson MP; Mahaffey KW; White HD; Todaro TG; Adams PX; Aylward PE; Granger CB
    J Am Coll Cardiol; 2009 Apr; 53(17):1503-9. PubMed ID: 19389560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study.
    Bagai A; Armstrong PW; Stebbins A; Mahaffey KW; Hochman JS; Weaver WD; Patel MR; Granger CB; Lopes RD
    Am Heart J; 2013 Nov; 166(5):913-9. PubMed ID: 24176448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction".
    French JK; Armstrong PW; Cohen E; Kleiman NS; O'Connor CM; Hellkamp AS; Stebbins A; Holmes DR; Hochman JS; Granger CB; Mahaffey KW
    Am Heart J; 2011 Jul; 162(1):89-97. PubMed ID: 21742094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Buller CE; Fu Y; Mahaffey KW; Todaro TG; Adams P; Westerhout CM; White HD; van 't Hof AW; Van de Werf FJ; Wagner GS; Granger CB; Armstrong PW
    Circulation; 2008 Sep; 118(13):1335-46. PubMed ID: 18779444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
    JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
    Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA;
    JAMA; 2006 Apr; 295(13):1519-30. PubMed ID: 16537725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Martel C; Granger CB; Ghitescu M; Stebbins A; Fortier A; Armstrong PW; Bonnefoy A; Theroux P
    Am Heart J; 2012 Jul; 164(1):43-51. PubMed ID: 22795281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients.
    Testa L; Van Gaal WJ; Bhindi R; Biondi-Zoccai GG; Abbate A; Agostoni P; Porto I; Andreotti F; Crea F; Banning AP
    J Thorac Cardiovasc Surg; 2008 Oct; 136(4):884-93. PubMed ID: 18954626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
    Hudson MP; Armstrong PW; O'Neil WW; Stebbins AL; Weaver WD; Widimsky P; Aylward PE; Ruzyllo W; Holmes D; Mahaffey KW; Granger CB
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):183-92. PubMed ID: 21304097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study.
    Brener SJ; Moliterno DJ; Aylward PE; van't Hof AW; Ruźyllo W; O'Neill WW; Hamm CW; Westerhout CM; Granger CB; Armstrong PW;
    Eur Heart J; 2008 May; 29(9):1127-35. PubMed ID: 18375399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial.
    Mehta SR; Yusuf S; Díaz R; Zhu J; Pais P; Xavier D; Paolasso E; Ahmed R; Xie C; Kazmi K; Tai J; Orlandini A; Pogue J; Liu L;
    JAMA; 2005 Jan; 293(4):437-46. PubMed ID: 15671428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Armstrong PW; Adams PX; Al-Khalidi HR; Hamm C; Holmes D; O'Neill W; Todaro TG; Vahanian A; Van de Werf F; Granger CB;
    Am Heart J; 2005 Mar; 149(3):402-7. PubMed ID: 15864228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.